
ACC 2022
Featured articles


Alirocumab significantly reduces high-risk coronary plaques

CONTENTS
Online First
Highlighted Original Research

POISE-3: Tranexamic acid for non-cardiac surgery
Treating chronic mild hypertension during pregnancy leads to better outcomes
New VOYAGER PAD data: Should patients with both PAD and CKD get rivaroxaban?

Alirocumab significantly reduces high-risk coronary plaques
Aggressive warming during non-cardiac surgery does not improve outcomes
Heart Failure and Cardiomyopathy
DIAMOND trial: Patiromer lowers risk of severe hyperkalaemia
Replacing septal reduction therapy with mavacamten for HCM
Surprise outcome for SODIUM-HF
Sotagliflozin SCORED MACE benefit
Omecamtiv mecarbil does not impact exercise capacity of patients with HFrEF

Symptomatic obstructive hypertrophic cardiomyopathy: long-term mavacamten control
Interventional and Structural Cardiology
COMPLETE revascularisation improves angina-related QoL
Plot twist for negative FAME 3 results: early QoL benefits of PCI
1-year CLASP TR results support tricuspid regurgitation repair

Head-to-head: post-TAVR edoxaban not better than DAPT
Chocolate Touch vs Lutonix catheters
No FLAVOUR difference between FFR and IVUS for PCI guidance
Myocardial Infarction
Low-resource countries benefit from global STEMI initiative
Sodium thiosulfate ineffective at cardiac protection
ICM-guided management did not improve MACE after MI
Prevention

PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation
RCT-IVVE trial: Do HF patients benefit from annual flu shots?
TRANSLATE-TIMI 70: Primary endpoint met but safety concerns for vupanorsen
Lipoprotein(a) slashed by 98% in APOLLO trial
